American Association for Cancer Research

sorry, we can't preview this file

crc-22-0028-s01.docx (14.61 kB)

Supplementary Table S1 from A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

Download (14.61 kB)
journal contribution
posted on 2023-04-04, 01:43 authored by Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Emily K. Bergsland, Edwin A. Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mark M. Moasser, Pamela N. Munster

A) Rationale for study drug dose interruption or reduction; B) Rationale for cisplatin dose interruption or reduction; C) Cisplatin dose intensity, stratified by dose level



The PI3K inhibitor alpelisib has limited activity alone, but there is interest in combinations in platinum-resistant tumors. In this phase Ib study of alpelisib with cisplatin, the objective response rate measured 29% but adverse events limited dose intensity. These promising results provide rationale for studying combinations with better tolerated platinum agents.